

EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373/35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/S-LDF87

July 29, 2021

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Dear Sir / Madam,

Sub: Outcome of the Board Meeting under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Ref: Scrip Code No. 524768

With reference to the captioned subject, please be informed that the Board of Directors of the Company at its meeting held today i.e., 29th July, 2021 through Video Conferencing has transacted the following business. The meeting began at 02.00 pm and concluded at 4.00pm.

1. The Board has considered and approved the Un-Audited Standalone quarterly financial results of the Company for the first quarter ended June 30, 2021. The Results will be made available on the website of the Company: <http://www.ebnl.org>, in due compliance with the Listing Regulations.
2. The Board decided to convene the 29th Annual General Meeting on Wednesday, September 15, 2021. The intimation of the same to the BSE and Investors will be given shortly.
3. General discussion about other matters as per the agenda of the meeting.

You are kindly requested to take this on record.


Thanking you,
Yours faithfully,
For Emmessar Biotech & Nutrition Limited


MSR Ayyangar
Managing Director
DIN: 00090266



Regd. Office & Factory: Plot No. T-3/2, MIDC Area, P.O. Box No. 39. Taloja – 410208.

Dist. Raigad. Maharashtra. Email: enquiries@ebnl.org Website: www.ebnl.org



EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001
Tel: 022-35661373/35664530 Email: enquiries@ebnl.org Website: www.ebnl.org
Investors Grievance Email: investors@ebnl.org CIN No. L24110MH1992PLC065942

EBN/S-LDF87A

July 29, 2021

The Manager
The Department of Corporate Service
BSE Limited
Floor 25, Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Dear Sir / Madam,

Sub: Regulation 33 of SEBI (LODR) Regulations, 2015–Un-Audited Standalone Financial Results of the Company for the quarter ended July 30, 2021.
Ref: Scrip Code No. 524768

Pursuant to provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors at its meeting held today, July 29, 2021, has approved the Un-Audited Standalone Financial Results of the Company for the quarter and year ended June 30, 2021.

We are enclosing herewith the following.

1. The Un-Audited Standalone Quarterly Financial Results of the Company for the quarter ended June 30, 2021
2. Limited Review Report dated July 29, 2021, by the Statutory Auditors on the Financial Results (Standalone) for the quarter ended June 30, 2021.

The Results will be made available on the website of the Company: <http://www.ebnl.org>.

You are kindly requested to take this on record.

Thanking you,
Yours faithfully,
For Emmessar Biotech & Nutrition Limited


MSR Ayyangar
Managing Director
DIN: 00090266



EMMESSAR BIOTECH & NUTRITION LIMITED
 Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State
 CIN: L24110MH1992PLC06594229

UNAUDITED FINANCIAL RESULTS (STANDLONE) FOR THE QUARTER ENDED 30TH JUNE 2021

Sr. No	Particulars	(Rupees in Lakhs)			
		Quarter Ended		Year Ended	
		30.06.2021 Unaudited	31.03.2021 Audited	30.06.2020 Audited	31.03.2021 Audited
	PART A				
1	Revenue from Operations	2.32	452.07	29.21	699.08
2	Other Income	37.81	36.27	19.33	146.56
	Total Income (1 + 2)	40.13	488.34	48.54	845.64
	PART B				
3	Expenses				
	Cost of material consumed	0.02	50.92	2.15	251.97
	Purchase of Stock-trade	0.00	7.33	4.80	12.14
	Change in Inventories of Finished goods	0.86	166.86	9.89	89.12
	Employee Benefit Expenses	17.95	17.70	12.38	63.84
	Depreciation & Amortisation of Assets	1.39	1.46	1.44	5.77
	Other Expenditure	11.11	111.47	15.43	197.35
	Total Expenses	31.33	355.74	46.09	620.19
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	8.80	132.60	2.45	225.45
5	Exceptional items	0.00	0.00	0.00	0
6	Profit / (loss) before tax (4 - 5)	8.80	132.60	2.45	225.45
7	Tax Expenses				
	1. Current Tax (MAT)	0.00	-47.00	0.00	-47.00
	2. Deferred Tax	0.00	-44.76	0.00	-44.76
	3. MAT Credit available	0.00	6.25	0.00	6.25
	4. Excess/short provision of earlier years	0.00	4.48	0.61	5.03
8	Net Profit / (loss) after tax (6 - 7)	8.80	51.57	3.06	144.97
9	Other Comprehensive Income	0.00	-1.14	0.00	-1.14
10	Total comprehensive income and Other Comprehensive Income	8.80	50.43	3.06	143.83
11	Paid-up Equity Share Capital -	499.61	499.61	499.61	499.61
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Earning per Shares				
	1. Basic	0.18	1.01	0.06	2.88
	2. Diluted	0.18	1.01	0.06	2.88

Notes:

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 29th July 2021 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The Company operated in two segments ie, Healthcare and rent on leasehold land during this quarter.
- Deferred tax & provision for taxation will be calculated annually.
- No Investor Compliant was received for the quarter ended 30th June 2021

Mumbai
29-Jul-21

MSR Ayyangar
Managing Director



EMMESSAR BIOTECH & NUTRITION LIMITED Regd Office: T-3/2, MIDC, Taloja, Raigad District, Maharashtra State CIN: L24110MH1992PLC06594229 Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2021					
[Rs. In Lakhs]					
		Quarter Ended			Year Ended
		30.06.2021 Unaudited	31.03.2021 Audited	30.06.2020 Audited	31.03.2021 Audited
1	1. Segment Revenue				
a	Healthcare	2.32	47.86	1.59	68.97
b	Fine Chemicals	0.00	404.22	27.62	630.10
c	Rent on Leasehold Land	33.78	33.78	16.29	135.13
d	Others	4.03	2.49	3.04	11.43
	Total:	40.13	488.35	48.54	845.63
	Less: Inter Segment Revenue	0.00	0.00	0.00	0.00
	Net Sales / Income from Operations	40.13	488.35	48.54	845.63
2	Segment Results (Profit / Loss) tax				
a	Healthcare	1.44	37.07	0.64	25.60
b	Fine Chemicals	0.00	91.81	3.85	158.99
c	Rent on Leasehold Land	33.55	33.78	16.06	135.13
d	Others	4.03	2.49	3.04	11.43
	Total:	39.02	165.15	23.59	331.15
	Less:				
	Interest	0.00	0.00	0.00	0.00
	Other Unallocable Expenditure (Net off)	30.22	32.55	21.14	105.7
	Total Profit before Tax & Exceptional items	8.80	132.60	2.45	225.45
3	Capital Employed (Segment Assets - Segment Liabilities)				
a	Healthcare	6.45	8.33	11.12	8.33
b	Fine Chemicals	0.00	219.77	93.42	219.77
c	Leasehold Land	0.91	1.14	1.85	1.14
d	Others	479.20	286.69	272.78	286.69
	Total:	486.56	515.93	379.17	515.93
Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature. The above results were taken on record at a meeting of the Board of Directors held on July 29th, 2021 Mumbai 29-Jul-21					
By order of the Board MSR Ayyangar Managing Director					



Tel : 2200 4465, 2206 7440
Fax : 91-22- 2200 0649
E-mail : mumbai@vsa.co.in
Website : www.vsa.co.in

V. Sankar Aiyar & Co.

CHARTERED ACCOUNTANTS
2-C, Court Chambers
35, New Marine Lines
Mumbai – 400 020

Independent Auditor's Review Report on Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

TO THE BOARD OF DIRECTORS OF

Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying statement of unaudited financial results of Emmessar Biotech & Nutrition Limited ("the Company") for the quarter ended June 30, 2021.
2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For V. Sankar Aiyar & Co.,
Chartered Accountants
(FRN. 109208W)**



Place: Mumbai
Date: July 29, 2021

V Mohan
Partner
(Membership No. 017748)
UDIN: 21017748AAAABJ8384